D. Norman

R. Hershberger, S. Sharma, A. Çobanoğlu, 1996, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.

A. Matas, J. Pirsch, Joshua Miller, 2007, Transplantation.

Primer on Transplantation

L. Turka, D. Norman, 2001 .

Squamous and basal cell carcinoma in heart transplant recipients.

R. Hershberger, F. Parker, A. Çobanoğlu, 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Late infection in cardiac allograft recipients: profiles, incidence, and outcome.

R. Hershberger, A. Starr, G. Pantely, 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Kidney and pancreas transplantation

A. Gaber, V. Ashby, J. Pirsch, 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

A novel DRB1*04 allele.

R. Endres, D. Norman, P. Wetzsteon, 2007, Tissue antigens.

A critical analysis of morbidity and mortality as it relates to recipient age following cardiac transplantation.

A. Starr, G. Pantely, A. Çobanoğlu, 1990, Clinical transplantation.

Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease.

A. Starr, G. Pantely, A. Çobanoğlu, 1988, The Journal of heart transplantation.

Lack of progressive "restrictive" physiology after heart transplantation despite intervening episodes of allograft rejection: comparison of serial rest and exercise hemodynamics one and two years after transplantation.

M. Morton, A. Starr, G. Pantely, 1990, The Journal of heart transplantation.

Serial Echocardiographic Findings Early After Heart Transplantation: Evidence for Reversible Right Ventricular Dysfunction and Myocardial Edema

A. Starr, J. Hosenpud, D. Norman, 1987, The Journal of heart transplantation.

Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil.

M. Pescovitz, B. Book, J. Kimball, 1995, Transplantation.

Prospective risk stratification in renal transplant candidates for cardiac death.

W. Bennett, J. Barry, D. Norman, 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Ten-year results of the Oregon program with 295 consecutive heart transplants in the Pacific Northwest.

A. Çobanoğlu, D. Norman, R. Hershberger, 1997, American journal of surgery.

Glomerular fibrin thrombi in ABO and crossmatch compatible renal allograft biopsies.

M. Troxell, D. Norman, A. Mittalhenkle, 2011, Pathology, research and practice.

Natural history of "silent" lupus nephritis.

W. Bennett, E. Bardana, D. Houghton, 1982, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A case control study of renal transplantation in patients with type I diabetes.

W. Bennett, J. Barry, D. Norman, 1992, Clinical transplantation.

SIGNIFICANCE OF DELAYED GRAFT FUNCTION IN CYCLOSPORINE‐TREATED RECIPIENTS OF CADAVER KIDNEY TRANSPLANTS

W. Bennett, J. Barry, D. Norman, 1988, Transplantation.

HLA‐identical sibling renal transplantation – a 21‐yr single‐center experience

W. Bennett, J. Barry, D. Norman, 1999, Clinical transplantation.

Interleukin-12 p40 m-RNA expression in human kidney allograft biopsies.

W. Bennett, D. Norman, A. D. de Mattos, 1997, Transplant immunology.

Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies.

M. Goldman, L. Chatenoud, D. Norman, 1993, Transplantation proceedings.

The clinical role of OKT3.

D. Norman, 1989, Cardiology clinics.

Cardiac allografts from high-risk donors: excellent clinical results.

A. Çobanoğlu, J. Hosenpud, D. Norman, 1994, The Annals of thoracic surgery.

A prospective, double‐blind, randomized study of high‐versus low‐dose OK3 induction immunosuppression in cadaveric renal transplantation

W. Bennett, J. Barry, J. Kimball, 1994 .

A prospective, double-blind, randomized study of high-versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation

W. Bennett, J. Barry, J. Kimball, 1994, Transplant international : official journal of the European Society for Organ Transplantation.

The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy.

W. Bennett, J. Barry, D. Norman, 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

OKT3 monoclonal antibody in pediatric kidney transplant recipients with recurrent and resistant allograft rejection.

J. Barry, S. Alexander, D. Norman, 1987, The Journal of pediatrics.

OKT3 monoclonal antibody reversal of acute renal allograft rejection unresponsive to conventional immunosuppressive treatments.

A. Monaco, M. W. Flye, J. Burdick, 1986, Progress in clinical and biological research.

Cytokine-release syndrome: differences between high and low doses of OKT3.

J. Barry, J. Kimball, D. Norman, 1993, Transplantation proceedings.

Pancreas Allograft Rejection: Analysis of Concurrent Renal Allograft Biopsies and Posttherapy Follow-Up Biopsies

M. Troxell, D. B. Koslin, D. Norman, 2010, Transplantation.

Renal transplantation across the ABO barrier using A2 kidneys.

W. Bennett, J. Barry, D. Norman, 1999, Transplantation.

The Addition of Sirolimus to Cyclosporine and Steroids Inhibits the Anti‐Equine Antibody Response in Renal Transplant Recipients Treated with Antithymocyte Globulin

M. Pescovitz, B. Book, J. Kimball, 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Factors associated with improvement in deceased donor renal allograft function in the 1990s.

S. Paraskevas, D. Keith, D. Norman, 2005, Journal of the American Society of Nephrology : JASN.

Trends in recipients , donors , transplants , and immunosuppression during the decade of the 1990

S. Paraskevas, D. Keith, D. Norman, 2005 .

The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors.

D. Heisey, F. Claas, T. Mohanakumar, 1998, The New England journal of medicine.

De novo thrombotic microangiopathy in two kidney transplant recipients from the same deceased donor: A case series

A. Olyaei, D. Roberts, T. Deloughery, 2020, Clinical transplantation.

A RANDOMIZED CLINICAL TRIAL OF INDUCTION THERAPY WITH OKT3 IN KIDNEY TRANSPLANTATION

Shu-chen Wu, T. Haverty, J. Thistlethwaite, 1993, Transplantation.

OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.

W. Bennett, J. Barry, J. Kimball, 1991, Transplantation proceedings.

Efficacy and safety of low molecular weight heparin in renal transplantation.

W. Bennett, J. Barry, A. Olyaei, 1998, Transplantation.

The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol.

J. Barry, D. Norman, A. Demattos, 2000, Transplantation.

Tubular transport capacity in human kidney cortex slices after prolonged preservation in Collins 2 solution.

W. C. Elliott, W. Bennett, J. Barry, 1982, Urology.

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

J. Squifflet, P. Brennan, H. Neumayer, 1999, The New England journal of medicine.

Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high‐ and low‐risk (D+R− and D−R−) profiles and does not adversely affect transplant rates

A. Olyaei, S. Orloff, D. Roberts, 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

THE INFLUENCE OF DONOR FACTORS OTHER THAN SEROLOGIC STATUS ON TRANSMISSION OF CYTOMEGALOVIRUS TO TRANSPLANT RECIPIENTS

S. Chou, D. Norman, 1988, Transplantation.

No effect of H-Y minor histocompatibility antigen in zero-mismatched living-donor renal transplants.

E. Edwards, D. Norman, O. P. Daily, 1994, Transplantation.

Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants.

W. Bennett, J. Barry, D. Norman, 1993, Transplantation proceedings.

Influence of acute tubular necrosis on first cadaver kidney transplant function.

W. Bennett, J. Barry, D. Norman, 1984, The Journal of urology.

Prolonged human kidney preservation by intracellular electrolyte flush followed by cold storage.

W. Bennett, J. Barry, D. Norman, 1984, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Preserved Endocrine Function in a Pancreas Transplant Recipient with Pancreatic Panniculitis and Antibody‐Mediated Rejection

M. Troxell, A. Olyaei, D. Norman, 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids.

A. A. Oni, R. Hershberger, A. Çobanoğlu, 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Donor-specific antibodies require preactivated immune system to harm renal transplant

T. Fehr, M. Zeier, P. Schemmer, 2016, EBioMedicine.

14th International HLA and Immunogenetics Workshop Prospective Chronic Rejection Project: a three-year follow-up analysis.

F. Christiansen, N. Lachmann, F. Heinemann, 2007, Clinical transplants.

VALACICLOVIR PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL TRANSPLANTATION: AN ECONOMIC EVALUATION

C. Legendre, D. Norman, M. Keating, 2000, Transplantation.

Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines

Matthew C. Fox, J. Stein, S. Arron, 2019, Transplant international : official journal of the European Society for Organ Transplantation.

Reversible acute renal allograft dysfunction due to gabapentin.

D. Norman, A. D. de Mattos, B. Gallay, 2000, Transplantation.

Time for reform in transplant program–specific reporting: AST/ASTS transplant metrics taskforce

J. Schold, L. Ratner, T. Pruett, 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Beneficial effect of pre-transplant splenectomy for leukopenia in primary cadaver kidney transplants.

W. Bennett, J. Barry, D. Norman, 1983, The Journal of urology.

Comparison of standard immunosuppression with adjuvant antilymphoblast globulin in primary cadaver kidney transplant survival.

W. Bennett, J. Barry, D. Norman, 1982, Urology.

Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection.

W. Bennett, J. Barry, J. Kimball, 1988, Transplantation.

Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study.

C. Schmid, B. Pereira, T. Wright, 1994, Kidney international.

Use of OKT4A (a murine monoclonal anti-CD4 antibody) in human organ transplantation: initial clinical experience.

R. Hershberger, W. Bennett, A. Çobanoğlu, 1993, Transplantation proceedings.

OKT4A (a murine IgG2a anti-CD4 monoclonal antibody) in human organ transplantation: pharmacokinetics and peripheral pharmacodynamics.

W. Lye, J. Kimball, D. Norman, 1993, Transplantation proceedings.

SUCCESSFUL CADAVER KIDNEY TRANSPLANTATION IN PATIENTS HIGHLY SENSITIZED BY BLOOD TRANSFUSIONS

J. Barry, D. Norman, P. Wetzsteon, 1985, Transplantation.

Immunological Assessment of the Transplant Patient

D. Norman, R. D. Santos, Eric D. Langewisch, 2014 .

Strategies to increase living donor kidney transplants.

J. Barry, D. Norman, M. Conlin, 2005, Urology.

Identification of high- and low-risk second kidney grafts.

M. Garovoy, D. Norman, B. Colombe, 1996, Transplantation.

HLA-DR mismatching correlates with early cardiac allograft rejection, incidence, and graft survival when high-confidence-level serological DR typing is used

M. A. Head, R. Hershberger, A. Çobanoğlu, 1994 .

HLA-DR mismatching correlates with early cardiac allograft rejection, incidence, and graft survival when high-confidence-level serological DR typing is used.

M. A. Head, R. Hershberger, A. Çobanoğlu, 1994, Transplantation.

14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic Rejection Project.

F. Christiansen, F. Heinemann, N. Mehra, 2007, Tissue antigens.

Long-Term Kidney Regraft Survival From Deceased Donors: Risk Factors and Outcomes in a Single Center

J. Barry, D. Norman, M. Arnol, 2008, Transplantation.

Reply: THE FLOW CYTOMETRY CROSSMATCH IN SECOND KIDNEY GRAFTS

D. Norman, K. Ault, B. Colombe, 1996 .

A comparison of 2 protocols for living-related renal transplantation in children: donor-specific transfusions versus cyclosporine.

J. Barry, S. Alexander, D. Norman, 1990, The Journal of urology.

A caveat to the MISSION Act: Perspective from a Veterans Administration transplant center

D. Norman, J. Lockridge, E. Maynard, 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Use of cytomegalovirus-seropositive donor kidneys in seronegative patients: results of prospective serotesting and matching in one center.

S. Chou, D. Norman, K. Henell, 1989, Transplantation proceedings.

OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies.

A. Monaco, D. Abramowicz, P. Kinnaert, 1995, Transplantation proceedings.

VALIDATION OF MODELS FOR PREDICTING AREA-UNDER-THE CURVE IN RENAL TRANSPLANT PATIENTS RECEIVING NEORAL™

W. Bennett, J. Barry, A. Olyaei, 1999 .

Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics

M. Pescovitz, D. Conti, B. Kiberd, 2000 .

Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics.

M. Pescovitz, D. Conti, B. Kiberd, 1999, Clinical transplantation.

Cytokine nephropathy during antilymphocyte therapy.

W. Bennett, D. Norman, T. Batiuk, 1993, Transplantation proceedings.

Kidney Biopsy Adequacy: A Metric-based Study

M. Troxell, D. Houghton, D. Norman, 2019, The American journal of surgical pathology.

Late Steroid Withdrawal and Cardiovascular Events in Kidney Transplant Recipients

D. Norman, A. D. de Mattos, M. Arnol, 2008, Transplantation.

Cadaver kidney transplantation in patients more than 65 years old

W. Bennett, J. Barry, D. Norman, 2004, World Journal of Urology.

An overview of the use of the monoclonal antibody OKT3 in renal transplantation.

D. Norman, 1988, Transplantation Proceedings.

The specificity of normal qualitative angiography in excluding cardiac allograft vasculopathy.

R. Hershberger, A. Çobanoğlu, J. Hosenpud, 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation.

J. Barry, A. Olyaei, D. Norman, 2005, Kidney international.

Cadaveric renal transplantation in a patient with primary hyperoxaluria. A case report.

W. Bennett, J. Barry, D. Norman, 1983, Transplantation.

Which cyclosporin formulation?

A. Olyaei, D. Norman, A. Demattos, 1996, The Lancet.

Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy.

S. Chou, R. Hershberger, A. Çobanoğlu, 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

African American living-kidney donors should be screened for APOL1 risk alleles.

C. Young, D. Cohen, D. Norman, 2011, Transplantation.

United network for organ sharing (UNOS) organ allocation policy and kidney utilization.

D. Norman, John D Scandling, Douglas J Norman, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

ABO-incompatible heart transplantation: a special case for the A2 donor.

R. Hershberger, A. Çobanoğlu, J. Hosenpud, 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Transplantation in General Medical Education

D. Norman, R. D. Santos, 2014 .

Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors.

M. Mori, Y. Shibagaki, A. Olyaei, 2006, Kidney international.

Depression in patients being evaluated for heart transplantation.

A. Starr, A. Çobanoğlu, J. Hosenpud, 1989, General hospital psychiatry.

Effect of donor recipient age match on survival after first deceased donor renal transplantation.

D. Keith, D. Norman, J. Prather, 2004, Journal of the American Society of Nephrology : JASN.

Long-standing donor diabetes and pathologic findings are associated with shorter allograft survival in recipients of kidney transplants from diabetic donors

V. Kung, D. Woodland, D. Norman, 2021, Modern Pathology.

A U.S. clinical study of Orthoclone OKT3 in renal transplantation.

J. Barry, D. Norman, C. Shield, 1987, Transplantation proceedings.

ORTHOCLONE OKT3: First-line therapy or last option?

D. Norman, C. Shield, 1986 .

The Kidney Transplant Wait‐List: Allocation of Patients to a Limited Supply of Organs

D. Norman, 2005, Seminars in dialysis.

Reversal of acute allograft rejection with monoclonal antibody

J. Barry, D. Norman, K. Henell, 1985 .

Cardiac risk stratification in renal transplantation using a form of artificial intelligence.

R A Wilson, W. Bennett, J. Barry, 1997, The American journal of cardiology.

OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival.

A. Monaco, Shu-chen Wu, P. Vereerstraeten, 1996, Kidney international.

Equine Anti-Thymocyte Globulin (ATGAM) administration in patient with previous rabbit Anti-Thymocyte Globulin (Thymoglobulin) induced serum sickness: A case report

A. Olyaei, D. Norman, J. Lockridge, 2017 .

Encephalopathy following the use of OKT3 in renal allograft transplantation.

J. Barry, D. Norman, F. Shihab, 1993, Transplantation proceedings.

Relation between recipient: donor body size match and hemodynamics three months after heart transplantation.

M. Morton, A. Starr, G. Pantely, 1989, The Journal of heart transplantation.

Effect of OKT3 antibody therapy on cytomegalovirus reactivation in renal transplant recipients

S. Chou, D. Norman, 1985 .

Mechanisms of Action and Overview of OKT3

D. Norman, 1995, Therapeutic drug monitoring.

The Clinical and Economic Benefit of CMV Matching in Kidney Transplant: A Decision Analysis

M. Schnitzler, D. Segev, D. Axelrod, 2021, Transplantation.

Renal function 27 years after unilateral nephrectomy for related donor kidney transplantation.

W. Bennett, J. Barry, D. Norman, 1988, The Journal of urology.

Use of A(2) kidneys for B and O kidney transplant recipients: report of a series of patients transplanted at a single center spanning a decade.

J. Barry, D. Norman, A. Alkhunaizi, 2001, Transplantation proceedings.

Factors in Cardiac Risk Stratification of Candidates for Renal Transplant

W. Bennett, J. Barry, D. Norman, 1999, Journal of cardiovascular risk.

W. Bennett, J. Barry, D. Norman, 1993, Transplantation proceedings.

Monoclonal antibody for reversal of acute renal allograft rejection in pediatric patients.

J. Barry, S. Alexander, D. Norman, 1985, Transplantation.

Identification of poorly performing transplant centers using the UNOS center-specific data.

R. Bollinger, L. Hunsicker, J. Burdick, 1997, Transplantation proceedings.

The lack of predictive value of preoperative psychologic distress for postoperative medical outcome in heart transplant recipients.

A. Starr, G. Pantely, A. Çobanoğlu, 1991, The Journal of Heart and Lung Transplantation.

Cytotoxic flow-cytometric crossmatches (flow-tox): a comparison with conventional cytotoxicity crossmatch techniques.

M. A. Head, W. Lye, D. Norman, 1992, Human immunology.

5.5-02 Cytotoxic flow crossmateches

M. A. Head, L. Fletcher, D. Norman, 1989 .

Methotrexate for the treatment of patients with multiple episodes of acute cardiac allograft rejection.

R. Hershberger, A. Çobanoğlu, J. Hosenpud, 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Immunogenetics and Immunologic Mechanisms of Rejection

D. Norman, Douglas J. Norman, 1991 .

Rationale for OKT3 monoclonal antibody treatment in transplant patients.

D. Norman, 1993, Transplantation proceedings.

Pediatric cadaver kidney transplants into adults.

W. Bennett, J. Barry, D. Norman, 1985, The Journal of urology.

Evidence for a second class II (Ia) antigenic system in rats linked to RT1.

C. Terranova, E. Milford, C. Carpenter, 1979, Transplantation proceedings.

OKT3 for treatment of rejection in renal transplantation

D. Norman, A. Demattos, 1993 .

Therapeutic use of OKT3 monoclonal antibody for acute renal allograft rejection.

J. Barry, D. Norman, B. Funnell, 1987, Nephron.